BioNTech will likely take 900 million eur write

BERLIN (Reuters) - Germany's BioNTech (NASDAQ:) on Formal foreign exchange trading platformMonday said it would likely take write-downs of up to 900 million euros ($947 million) in the third quarter after its partner (NYSE:) reported similar charges on their COVID-19 vaccine business last week.

Pfizer on Friday said it will take $900 million of inventory write-offs and other charges for the jointly developed vaccine, branded as Comirnaty, on top of much larger write-offs on Pfizer's own COVID treatment Paxlovid.

BioNTech will likely "recognize the effect of Pfizer's inventory write-offs and other charges related to Comirnaty in the third quarter of 2023 up to 0.9 billion euros, which represents BioNTech's half of the gross profit-sharing agreement with Pfizer", it said in a statement.

BioNTech, which is entitled to receive vaccine-related profit share payments from its U.S. partner, said the write-offs would also reduce its 2023 revenues.

A BioNTech spokesperson on Monday declined to comment on the company's current outlook, which is for COVID-19 vaccine revenues of about 5 billion euros in 2023.

The company is scheduled to release detailed third-quarter figures on Nov. 6.

($1 = 0.9498 euros)

Statement: The content of this article does not represent the views of FTI website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!